<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431325</url>
  </required_header>
  <id_info>
    <org_study_id>2013P002669</org_study_id>
    <secondary_id>1R01HL123351-01</secondary_id>
    <nct_id>NCT02431325</nct_id>
  </id_info>
  <brief_title>A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV</brief_title>
  <official_title>A Study to Investigate Gastrointestinal Epithelial Integrity and Arterial Inflammation in Individuals With and Without HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ragon Institute of MGH, MIT and Harvard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether teduglutide can repair a &quot;leaky&quot;&#xD;
      gut, decrease inflammation, and prevent or treat plaque, a build-up of fat and other&#xD;
      materials in the blood vessels of the heart, in people with HIV. HIV disease is linked to&#xD;
      inflammatory changes and leakiness of the gut. These changes or conditions may increase the&#xD;
      risk of developing heart and blood vessel disease. The investigators believe teduglutide can&#xD;
      help repair the gut barrier in people with HIV, leading to a decrease in inflammation and&#xD;
      plaque in the blood vessels of the heart.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As more people with HIV gain access to combination antiretroviral therapy (cART),&#xD;
      cardiovascular disease has become increasingly prevalent and a significant cause of&#xD;
      mortality. Activation of the innate immune system may stimulate inflammatory mechanisms of&#xD;
      atherosclerosis development. Loss of gastrointestinal (GI) mucosal epithelial integrity and&#xD;
      loss of CD4+ T-lymphocytes in the intestinal lamina propria occur in HIV-infected patients&#xD;
      and are not fully restored by cART. Translocation of microbial products from the intestinal&#xD;
      lumen into the systemic circulation has been demonstrated to be increased in HIV-infected&#xD;
      patients and the investigators hypothesize that it is a key driver of monocyte and macrophage&#xD;
      activation. In turn, these pro-inflammatory monocytes and macrophages can induce&#xD;
      atherosclerotic disease development. The purpose of the research study is to determine the&#xD;
      effects of a glucagon-like peptide-2 analog, teduglutide, on intestinal epithelial integrity,&#xD;
      microbial translocation across the gut lumen, markers of innate immune system activation&#xD;
      including the monocyte transcriptome, bone, arterial inflammation, and atherosclerosis in a&#xD;
      6-month randomized, double-blind placebo-controlled proof of concept trial in HIV-infected&#xD;
      individuals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">January 21, 2021</completion_date>
  <primary_completion_date type="Actual">January 21, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in soluble CD14 concentration</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in intestinal epithelial integrity</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in arterial target to background ratio of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) uptake</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in intestinal CD4+ T-cells</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plaque volume on cardiac computed tomography angiography</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin A1c percentage</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostatic Model Assessment-Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral adipose tissue (VAT) area</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subcutaneous adipose tissue (SAT) area</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body mass index (BMI)</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in soluble CD163 concentration</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in intestinal fatty acid binding protein concentration</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral density</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depressive symptoms</measure>
    <time_frame>Change from baseline at week 12 and at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive performance, defined as a global neurocognitive z-score</measure>
    <time_frame>Change from baseline at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in domain-specific cognitive performance, defined as a domain-specific neurocognitive z-score</measure>
    <time_frame>Change from baseline at week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Teduglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teduglutide, subcutaneous injection, 0.05 mg/kg/day, 6 months duration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, subcutaneous injection, 6 months duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide</intervention_name>
    <arm_group_label>Teduglutide</arm_group_label>
    <other_name>Gattex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women age 21-65 with previously diagnosed HIV disease&#xD;
&#xD;
          2. Stable anti-retroviral therapy (ART) as defined by no changes in ART regimen for &gt;6&#xD;
             months&#xD;
&#xD;
          3. HIV viral load &lt; 200 copies/mL&#xD;
&#xD;
          4. To be eligible for colonoscopy procedure, laboratory values that meet the following&#xD;
             criteria:&#xD;
&#xD;
               1. Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
               2. Absolute neutrophil count ≥ 1000/mm3&#xD;
&#xD;
               3. Platelet count ≥ 100,000/mm3&#xD;
&#xD;
               4. Prothrombin time (PT) &lt; 1.2 x upper limit of normal (ULN)&#xD;
&#xD;
               5. Partial thromboplastin time (PTT) &lt; 1.5 x ULN&#xD;
&#xD;
        4. Ability and willingness to give written informed consent and to comply with study&#xD;
        requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of clinically significant gastrointestinal disease including but not limited&#xD;
             to: colon cancer, intestinal obstruction, ulcerative colitis, Crohn's disease, or&#xD;
             history of C. difficile within the past 3 months&#xD;
&#xD;
          2. First-degree relative with history of colon cancer&#xD;
&#xD;
          3. Active gall bladder, biliary or pancreatic disease&#xD;
&#xD;
          4. Female subject who is pregnant, nursing or less than 8 weeks post partum.&#xD;
&#xD;
          5. Use of any immunomodulatory agents within 30 days prior to study enrollment&#xD;
&#xD;
          6. History of intolerance, sensitivity, allergy or anaphylaxis to benzodiazepines or&#xD;
             other narcotics to be used during the colonoscopy or upper endoscopy procedure&#xD;
&#xD;
          7. Contraindication to beta-blocker (including moderate to severe asthma or heart block)&#xD;
             or nitroglycerin use as these drugs are given as part of the standard cardiac CT&#xD;
             protocol. Previous allergic reaction to beta blocker or nitroglycerin.&#xD;
&#xD;
          8. Patients with previous allergic reactions to iodine-containing contrast media&#xD;
&#xD;
          9. Renal disease or creatinine &gt;1.5 mg/dL (contrast will be administered during CT&#xD;
             angiography of the heart)&#xD;
&#xD;
         10. History of requiring antibiotic prophylaxis for invasive procedures&#xD;
&#xD;
         11. History of myocardial infarction, decompensated cirrhosis, or any other condition that&#xD;
             in the opinion of the investigator will compromise ability to participate in the study&#xD;
&#xD;
         12. Currently taking anticoagulants including but not limited to: heparin (Hep-Lock,&#xD;
             Hep-Pak), Hep-Pak CVC, Heparin Lock Flush), warfarin (Coumadin), tinzaparin (Innohep),&#xD;
             enoxaparin (Lovenox), danaparoid (Orgaran), dalteparin (Fragmin), clopidogrel&#xD;
             (Plavix), prophylactic aspirin, and regular NSAID use&#xD;
&#xD;
         13. Subject taking any of the following medications: statins, systemic steroids (inhaled&#xD;
             or nasal steroid therapy is permitted), interleukins, systemic interferons (e.g. local&#xD;
             injection of interferon alpha for treatment of HPV is permitted), systemic&#xD;
             chemotherapy including oral chemotherapeutic agents, methotrexate, octreotide, growth&#xD;
             hormone, antiarrhythmics including digoxin, antiepileptics, immunosuppressants,&#xD;
             vancomycin, rifampin, aminoglycosides, clonidine, prazosin, lithium and&#xD;
             ritonavir-boosted lopinavir (Kaletra).&#xD;
&#xD;
         14. Subject has had two or more endoscopy procedures (sigmoidoscopy, upper endoscopy or&#xD;
             colonoscopy) within the past 12 months for clinical purposes or other research&#xD;
             studies.&#xD;
&#xD;
         15. Body weight greater than 300 lbs due to CT scanner table limitations&#xD;
&#xD;
         16. Active illicit drug use&#xD;
&#xD;
         17. Patients who report any significant radiation exposure over the course of the year&#xD;
             prior to randomization. Significant exposure is defined as:&#xD;
&#xD;
               1. More than 2 percutaneous coronary interventions (PCI) within 12 months of&#xD;
                  randomization&#xD;
&#xD;
               2. More than 2 myocardial perfusion studies within the past 12 months&#xD;
&#xD;
               3. More than 2 CT angiograms within the past 12 months&#xD;
&#xD;
               4. Any subjects with history of radiation therapy&#xD;
&#xD;
         18. Patients already scheduled or being considered for a procedure or treatment&#xD;
&#xD;
               1. requiring significant radiation exposure (e.g., radiation therapy, PCI, or&#xD;
                  catheter&#xD;
&#xD;
               2. ablation of arrhythmia) within 12 months of randomization&#xD;
&#xD;
         19. History of malignancy&#xD;
&#xD;
         20. Prior recipient of a HIV vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Lo, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2015</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Janet Lo, MD</investigator_full_name>
    <investigator_title>Assistant Professor in Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Microbial Translocation</keyword>
  <keyword>Teduglutide</keyword>
  <keyword>Gastrointestinal Permeability</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teduglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

